Skip to results
Modify your search
NARROW
1-20 of 99
Authors: Laurent Peyrin-Biroulet
Journal Article
TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WITH RO7790121 DEMONSTRATES EARLY CLINICAL RESPONSE AND SYMPTOM IMPROVEMENT – RESULTS FROM THE PHASE 2B TUSCANY-2 TRIAL
Inflammatory Bowel Diseases, Volume 31, Issue Supplement_1, February 2025, Page S12, https://doi.org/10.1093/ibd/izae282.028
Published: 28 February 2025
Journal Article
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Inflammatory Bowel Diseases, izae253, https://doi.org/10.1093/ibd/izae253
Published: 25 October 2024
Journal Article
Screen Failures and Causes in Inflammatory Bowel Disease Randomized Controlled Trials: A Study of 16 913 Screened Patients Get access
Inflammatory Bowel Diseases, izae233, https://doi.org/10.1093/ibd/izae233
Published: 26 September 2024
Journal Article
Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis
Inflammatory Bowel Diseases, izae204, https://doi.org/10.1093/ibd/izae204
Published: 16 September 2024
Journal Article
Implications of von Willebrand Factor in Inflammatory Bowel Diseases: Beyond Bleeding and Thrombosis Get access
Inflammatory Bowel Diseases, Volume 30, Issue 12, December 2024, Pages 2500–2508, https://doi.org/10.1093/ibd/izae142
Published: 03 July 2024
Journal Article
Target Trial Emulation: Improving the Quality of Observational Studies in Inflammatory Bowel Disease Using the Principles of Randomized Trials
Inflammatory Bowel Diseases, Volume 31, Issue 3, March 2025, Pages 843–849, https://doi.org/10.1093/ibd/izae131
Published: 11 June 2024
Journal Article
EDITOR'S CHOICE
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Inflammatory Bowel Diseases, Volume 30, Issue 12, December 2024, Pages 2245–2258, https://doi.org/10.1093/ibd/izae024
Published: 09 March 2024
Journal Article
COMPARATIVE EFFICACY AND SAFETY OF SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE AND ULCERATIVE COLITIS: AN INDIRECT COMPARISON FROM RANDOMIZED CONTROLLED TRIALS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S4–S5, https://doi.org/10.1093/ibd/izae020.011
Published: 25 January 2024
Journal Article
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials
Inflammatory Bowel Diseases, Volume 30, Issue 12, December 2024, Pages 2335–2346, https://doi.org/10.1093/ibd/izae004
Published: 25 January 2024
Journal Article
The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease
Inflammatory Bowel Diseases, Volume 30, Issue 11, November 2024, Pages 2064–2075, https://doi.org/10.1093/ibd/izad294
Published: 22 December 2023
Journal Article
Disease Clearance is not Synonymous with Cure
Inflammatory Bowel Diseases, Volume 30, Issue 3, March 2024, Page 509, https://doi.org/10.1093/ibd/izad236
Published: 05 October 2023
Journal Article
Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert Consensus
Inflammatory Bowel Diseases, Volume 30, Issue 6, June 2024, Pages 1009–1017, https://doi.org/10.1093/ibd/izad159
Published: 07 August 2023
Journal Article
EDITOR'S CHOICE
Health Care Disparities, Social Determinants of Health, and Emotional Impacts in Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient Survey
Inflammatory Bowel Diseases, Volume 29, Issue 11, November 2023, Pages 1681–1692, https://doi.org/10.1093/ibd/izad102
Published: 10 June 2023
Journal Article
Deep Dive Into MicroRNAs in Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 986–999, https://doi.org/10.1093/ibd/izac250
Published: 21 December 2022
Journal Article
Impact of Crohn’s Disease Therapies on Histology in Randomized Controlled Trials: Systematic Review With Meta-analysis
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1231–1243, https://doi.org/10.1093/ibd/izac203
Published: 17 October 2022
Journal Article
Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 Study
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 579–588, https://doi.org/10.1093/ibd/izac119
Published: 11 July 2022
Journal Article
Early Biological Therapy in Operated Crohn’s Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 539–547, https://doi.org/10.1093/ibd/izac110
Published: 28 May 2022
Journal Article
Prevalence of and Factors Associated with Respiratory Symptoms Among Patients with Inflammatory Bowel Disease: A Prospective Study
Inflammatory Bowel Diseases, Volume 29, Issue 2, February 2023, Pages 207–216, https://doi.org/10.1093/ibd/izac062
Published: 08 April 2022
Journal Article
EFFICACY OF BIOLOGIC DRUGS IN SHORT-DURATION VERSUS LONG-DURATION INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND INDVIDUAL-PATIENT-DATA METANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S11, https://doi.org/10.1093/ibd/izac015.017
Published: 22 January 2022
Journal Article
AN ONLINE SURVEY AMONG US PATIENTS WITH IMMUNE-MEDIATED CONDITIONS: BELIEFS ABOUT BIOSIMILARS FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 28, Issue Supplement_1, February 2022, Page S101, https://doi.org/10.1093/ibd/izac015.163
Published: 22 January 2022
